Moderna (MRNA) closed at $54.26 in the latest trading session, marking a +2.69% move from the prior day. This change outpaced the S&P 500's 0.8% gain on the day. Meanwhile, the Dow lost 0.15%, and the Nasdaq, a tech-heavy index, added 1.6%.
The biotechnology company's stock has dropped by 2.02% in the past month, falling short of the Medical sector's loss of 0.77% and the S&P 500's gain of 5.15%.
The investment community will be paying close attention to the earnings performance of Moderna in its upcoming release. On that day, Moderna is projected to report earnings of -$2.28 per share, which would represent year-over-year growth of 9.52%. Meanwhile, our latest consensus estimate is calling for revenue of $229.83 million, up 112.81% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$7.01 per share and revenue of $2.08 billion, indicating changes of +3.44% and +7.13%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Moderna. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.59% decrease. Currently, Moderna is carrying a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 95, positioning it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Moderna, Inc. (MRNA): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).